Lipella Pharmaceuticals Inc. (LIPO)
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
$3.43M
Dr. Jonathan Kaufman M.B.A., Ph.D.
4.00
Pittsburgh, PA
Dec 19, 2022
-0.70
$-0.61
10.42
11.27
114.00%
7.04%
0.88
2.11
0.06
10.51
215.80%
260.69%
Similar stocks (10)
Celcuity Inc.
CELC
Eliem Therapeutics, Inc.
ELYM
Acrivon Therapeutics, Inc. Common Stock
ACRV
Inhibrx, Inc.
INBX
Fennec Pharmaceuticals Inc.
FENC
Anebulo Pharmaceuticals, Inc.
ANEB
ImmuCell Corporation
ICCC
Monopar Therapeutics Inc.
MNPR
Senti Biosciences, Inc.
SNTI
Protagenic Therapeutics, Inc.
PTIX
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (10)
Celcuity Inc.
CELC
Eliem Therapeutics, Inc.
ELYM
Acrivon Therapeutics, Inc. Common Stock
ACRV
Inhibrx, Inc.
INBX
Fennec Pharmaceuticals Inc.
FENC
Anebulo Pharmaceuticals, Inc.
ANEB
ImmuCell Corporation
ICCC
Monopar Therapeutics Inc.
MNPR
Senti Biosciences, Inc.
SNTI
Protagenic Therapeutics, Inc.
PTIX
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%